Proctitis ulcerosa activa y refractaria: Una puesta al día

• GINO CASELLI M ^[1] ; GEORGE PINEDO M ^[1] ; ÁLVARO ZÚÑIGA D ^[1] ; MANUEL ÁLVAREZ L ^[1]
  1. [1] Pontificia Universidad Católica de Chile

     Pontificia Universidad Católica de Chile

     Santiago, Chile

     
• Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 138, Nº. 1, 2010, págs. 109-116
• Idioma: español
• Títulos paralelos:
  • Active and refractory ulcerative proctitis: An update
• Enlaces
  • Texto completo
• Resumen

  • Ulcerative colitis (UC) is a chronic inflammatory disease of unknown etiology that affects a variable length of the colon, starting from the rectum. When the disease is confined to the rectum is called ulcerative proctitis (UP). Several studies have unsuccessfully attempted to determine the factors that determine the extent of involvement. The goals of therapy in UP are to induce and maintain remission of symptoms and disease. Topical treatment with 5-aminosalicylates (5-ASA) is the treatment of choice to induce remission. In the maintenance phase, long-term follow up studies suggest that treatment with 5-ASA is better than placebo, to maintain the disease inactive. For those patients that do not respond to treatment with topical 5-ASA or have a moderate to severe disease, there are additional therapies such as oral 5-ASA, topical or systemic corticosteroids, immunomodulators, biological therapies (Infliximab) and cyclosporine. Surgery is seldom needed.